Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 155812

Tuesday, 01/29/2013 3:21:26 PM

Tuesday, January 29, 2013 3:21:26 PM

Post# of 257580
Curious error in SA transcript of BMY CC:

http://seekingalpha.com/article/1131001-bristol-myers-squibb-s-ceo-discusses-q4-2012-results-earnings-call-transcript

(Lamberto Andreotti, CEO): Eliquis has a real differentiated profile, and we were very encouraged to see the approvals in different parts of the world, reflects the risk rate action versus Warfarin in all three important outcomes of strong reduction, nasal bleeding and all because of that. So good clinical data and labels reflecting that clinical data.

The word nasal should be major, which is not that close in sound.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up